| Authors: |
Mercer LD; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA., Seña AC; University of North Carolina at Chapel Hill, Institute for Global Health and Infectious Diseases, Chapel Hill, NC, USA., Colgate ER; The Vaccine Testing Center, Department of Microbiology and Molecular Genetics, University of Vermont Larner College of Medicine, Burlington, VT, USA., Crothers JW; The Vaccine Testing Center, Department of Microbiology and Molecular Genetics, University of Vermont Larner College of Medicine, Burlington, VT, USA; Department of Pathology and Laboratory Medicine, University of Vermont Larner College of Medicine, Burlington, VT, USA., Wright PF; Geisel School of Medicine, Dartmouth, Hanover, NH, USA., Al-Ibrahim M; Pharmaron CPC, Baltimore, MD, USA., Tritama E; PT Bio Farma, Bandung, Indonesia., Vincent A; Polio and Picornavirus Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA., Mainou BA; Polio and Picornavirus Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA., Zhang Y; Polio and Picornavirus Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA., Konopka-Anstadt J; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA., Bandyopadhyay AS; Bill & Melinda Gates Foundation, Seattle, WA, USA., Fix A; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA., Konz JO; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA., Gast C; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA. Electronic address: cgast@path.org. |
